Gil Blum
Needham & Company, LLC, Research Division
Good morning, everyone. My name is Gil Blum, and I’m a senior biotech analyst here at Needham & Company, and welcome for joining our second day of the Needham Healthcare Conference. It is a pleasure to have with me today, Precision Bioscience’s team, Alex Kelly, the Chief Financial Officer; and Cassie Gorsuch, the Chief Science Officer.
And with that, Alex, feel free to start your presentation.
John Kelly
CFO & Principal Accounting Officer
Great. Thanks very much. Good to be here, Gil, and thank you to the Needham team for inviting us to present at the conference. So Cassie, if you can advance the next slide. Quickly, just as Gil introduced, I’m the CFO at Precision, and Cassie Gorsuch is our Chief Scientific Officer.
Next slide. Before I begin, I would just remind you that some of the statements that Cassie and I make this morning might be considered forward-looking statements. As a result, you should refer to our 10-K, which was filed in March, for any forward-looking statements that you should be aware of.
So with that, next slide. So what is Precision Biosciences? Precision Biosciences was founded as a spin-off from Duke in 2006. So we’re celebrating our 20th birthday this year. Our Co-Founders, Jeff Smith and others developed the ARCUS gene editing platform, and that has been the source of our company, and we are dedicated to improving the lives of patients through our in vivo gene editing platform. So as I mentioned, this is proprietary to Precision Biosciences. Our Co-Founder, Jeff Smith, is also our Chief
